Our group has shown that HER2-transgenic mice treated with the HER2/EGFR dual kinase inhibitor lapatinib (45) or the EGFR inhibitor gefitinib (46) have delayed development of HER2-positive mammary tumors. The gene discussed is ERBB2; the disease is breast cancer.